Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biosource International -- Ignore unavailable to you. Want to Upgrade?

To: milton who wrote (350)	12/7/1997 9:39:00 AM
From: Joe Dancy	Read Replies (2) \| Respond to of 696

Here's my latest (biased) take on BIOI Milton: *** BIOSOURCE INTERNATIONAL (BIOI) - Growth/PE ratio of 2.5: Three analysts have a "strong buy", and one has a "hold" opinion on BIOI. Based on the consensus earnings estimates for the fiscal year ending 12/98, the forward price-earnings ratio is 10.8. With an estimated 5 year earnings growth rate of 27.5% annually, the estimated growth rate/forward price- earnings ratio is an excellent 2.5 - a very strong buy. BIOI also has a price-to-book ratio of 1.7 - less than the industry average of 3.6 and the S&P 500 average of 5.5, so there is some downside protection here. Market capitalization is around $50 million - a microcap. The company provides equipment and testing supplies to the biotech industry - an industry that is growing strongly but is very risky. BIOI, as a supplier to the industry, is a less risky play than companies developing biotech drugs - yet should share in the growth. **** Best - Joe